Spark Therapeutics leaps on news of $15 million milestone payment

5 January 2017

US gene therapy company Spark Therapeutics (Nasdaq: ONCE) saw its share rise 10.8% to $59.49 on Wednesday after it announced receipt of an interim payment.

Spark says it has earned a $15 million payment for achieving a pre-specified safety and efficacy profile development milestone in the ongoing hemophilia B Phase I/II trial of investigational SPK-9001, under its collaboration with US pharma giant Pfizer (NYSE: PFE). SPK-9001 has received breakthrough therapy and orphan product designations from the US Food and Drug Administration.

“We continue to make strong, tangible progress with our hemophilia pipeline, and achievement of this second milestone marks further advancement in the development of our investigational gene therapy for hemophilia B,” said Jeffrey Marrazzo, chief executive of Spark Therapeutics, adding: “We look forward to reporting additional data as we continue to document the clinical experience with SPK-9001.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK